A Phase 3, multicenter, randomized, double-blind, placebocontrolled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and highrisk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Z-Nr.: 410
Chemo,Zielgerichtet